Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline

We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Edgewise Therapeutics, Inc. is among the best Robinhood stocks

TheFly reported on March 17 that JPMorgan increased its price target for EWTX from $34 to $45 while keeping an Overweight rating on the stock. The firm also added EWTX to its Analyst Focus List as a growth opportunity, highlighting optimism around upcoming pipeline catalysts, especially renewed attention on EDG-7500. Anticipation builds for the full 12-week data expected in Q2, which could significantly influence the fundamental outlook for EDG-7500. JPMorgan views the overall setup for EWTX in 2026 as increasingly favorable, reflecting confidence in the company’s potential and the opportunities presented by its pipeline developments.

Separately, earlier on March 10, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shared long-term results from its MESA open-label extension study evaluating sevasemten in Becker muscular dystrophy, a condition with no approved treatments. The findings indicate that patients on sevasemten maintained stable functional abilities over 3.5 years, contrasting with the expected decline observed in the Becker natural history.

Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline

After prior 12-month ARCH and CANYON assessments, continued follow-ups confirmed sustained stabilization and a favorable safety profile with extended exposure. The company plans to release top-line data from the placebo-controlled GRAND CANYON pivotal cohort in the fourth quarter, which could support sevasemten’s progression toward regulatory approval for this underserved patient population.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical‑stage biopharmaceutical company developing novel precision therapies for serious muscle disorders, including Duchenne and Becker muscular dystrophies and cardiac conditions, with an advanced pipeline of small‑molecule drug candidates targeting muscle biology.

While we acknowledge the risk and potential of EWTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EWTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.